Correlation Between Franklin Genomic and Fidelity MSCI

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Franklin Genomic and Fidelity MSCI at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Franklin Genomic and Fidelity MSCI into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Franklin Genomic Advancements and Fidelity MSCI Financials, you can compare the effects of market volatilities on Franklin Genomic and Fidelity MSCI and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Franklin Genomic with a short position of Fidelity MSCI. Check out your portfolio center. Please also check ongoing floating volatility patterns of Franklin Genomic and Fidelity MSCI.

Diversification Opportunities for Franklin Genomic and Fidelity MSCI

-0.72
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Franklin and Fidelity is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Franklin Genomic Advancements and Fidelity MSCI Financials in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fidelity MSCI Financials and Franklin Genomic is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Franklin Genomic Advancements are associated (or correlated) with Fidelity MSCI. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fidelity MSCI Financials has no effect on the direction of Franklin Genomic i.e., Franklin Genomic and Fidelity MSCI go up and down completely randomly.

Pair Corralation between Franklin Genomic and Fidelity MSCI

Given the investment horizon of 90 days Franklin Genomic is expected to generate 12.03 times less return on investment than Fidelity MSCI. In addition to that, Franklin Genomic is 1.12 times more volatile than Fidelity MSCI Financials. It trades about 0.01 of its total potential returns per unit of risk. Fidelity MSCI Financials is currently generating about 0.09 per unit of volatility. If you would invest  4,726  in Fidelity MSCI Financials on September 2, 2024 and sell it today you would earn a total of  2,605  from holding Fidelity MSCI Financials or generate 55.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Franklin Genomic Advancements  vs.  Fidelity MSCI Financials

 Performance 
       Timeline  
Franklin Genomic Adv 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Franklin Genomic Advancements has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong essential indicators, Franklin Genomic is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
Fidelity MSCI Financials 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Fidelity MSCI Financials are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain fundamental indicators, Fidelity MSCI disclosed solid returns over the last few months and may actually be approaching a breakup point.

Franklin Genomic and Fidelity MSCI Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Franklin Genomic and Fidelity MSCI

The main advantage of trading using opposite Franklin Genomic and Fidelity MSCI positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Franklin Genomic position performs unexpectedly, Fidelity MSCI can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fidelity MSCI will offset losses from the drop in Fidelity MSCI's long position.
The idea behind Franklin Genomic Advancements and Fidelity MSCI Financials pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges